Preliminary Phase II data for Zafgen Inc.'s beloranib provide the first clinical support for the company's hypothesis that the compound could compete with bariatric surgery to treat obesity.

While the data cover only a handful of patients treated for 12 weeks, two clinicians told BioCentury the trends suggest beloranib could provide weight loss greater than recently approved obesity drugs, and equal to or better than bariatric surgery.